Skip to main content
SpringerLink
Log in

Breast Cancer Cardio-Oncology

  • Chapter
  • First Online:
Cardio-Oncology

  • 882 Accesses

Abstract

Cardiovascular toxicity is a potential short- or long-term complication of breast cancer therapies. Cytotoxics, such as anthracyclines, and some targeted agents, are known to increase risk of clinically significant cardiac dysfunction. Described toxicities can be either reversible or irreversible and may interfere with the ability to provide anticancer therapy. Assessment of the prevalence, type, and severity of cardiac toxicity caused by cancer treatments, as well as long-term follow-up on the exact profile and outcomes of cardiac side effects, is a critical topic for patient management. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents. Further progress in patient care will require a dynamic partnership between oncologists and cardiologists, and the development of a new generation of “cardio-oncology” clinicians and investigators. Organized collaboration between oncologists, cardiologists, and regulatory agencies can support development of programs essential for anticancer agents with cardiac safety concerns.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–6.

    Article  CAS  PubMed  Google Scholar 

  2. Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53:105–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459–65.

    Article  CAS  PubMed  Google Scholar 

  4. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386–90.

    Article  CAS  PubMed  Google Scholar 

  5. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–21.

    Article  CAS  PubMed  Google Scholar 

  6. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987;19(8):817–28.

    Article  CAS  PubMed  Google Scholar 

  7. Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol. 2003;63(4):849–61.

    Article  CAS  PubMed  Google Scholar 

  8. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006;5:791–809.

    Article  CAS  PubMed  Google Scholar 

  9. Raschi E, Vasina V, Ursino MG, et al. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther. 2010;125:196–218.

    Article  CAS  PubMed  Google Scholar 

  10. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–22.

    Article  CAS  PubMed  Google Scholar 

  11. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treatment with high-dose chemotherapy. Ann Oncol. 2002;13:710–5.

    Article  CAS  PubMed  Google Scholar 

  12. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007;7:129–34.

    Article  CAS  PubMed  Google Scholar 

  13. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.

    Article  CAS  PubMed  Google Scholar 

  14. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25–36.

    Article  CAS  PubMed  Google Scholar 

  15. Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114–8.

    CAS  PubMed  Google Scholar 

  16. Gottdiener JS, Appelbaum JR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758–63.

    Article  CAS  PubMed  Google Scholar 

  17. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–13.

    Article  CAS  PubMed  Google Scholar 

  18. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

    Article  CAS  PubMed  Google Scholar 

  20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.

    Article  CAS  PubMed  Google Scholar 

  21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  CAS  PubMed  Google Scholar 

  22. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–9.

    Article  CAS  PubMed  Google Scholar 

  23. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. FinHer Study Investigators Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–20.

    Article  CAS  PubMed  Google Scholar 

  24. Chien KR. Herceptin and the heart: a molecular modifier of cardiac failure. N Engl J Med. 2006;354:789–90.

    Article  CAS  PubMed  Google Scholar 

  25. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26:60–70.

    CAS  PubMed  Google Scholar 

  26. Shell SA, Lyass L, Trusk PB, et al. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle. 2008;7:1769–75.

    Article  CAS  PubMed  Google Scholar 

  27. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679–86.

    Article  PubMed  Google Scholar 

  28. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  CAS  PubMed  Google Scholar 

  29. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–81.

    Article  CAS  PubMed  Google Scholar 

  30. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–20.

    Article  CAS  PubMed  Google Scholar 

  31. Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011;17:6438.

    Article  Google Scholar 

  32. Pituskin E, Haykowsky M, Mackey JR, et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies In Cardiology Oncology REsearch Trial (MANTICORE 101 Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodelling among patients with HER+ early breast cancer using cardiac MRI. BMC Cancer. 2011;11:318.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Huh WW, Jaffe N, Durand JB, et al. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus continuous infusion. Pediatr Hematol Oncol. 2010;27:546–57.

    Article  CAS  PubMed  Google Scholar 

  34. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol. 1990;1:409–14.

    Article  CAS  PubMed  Google Scholar 

  35. Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori. 1982;68:505–10.

    CAS  PubMed  Google Scholar 

  36. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17:729–36.

    CAS  PubMed  Google Scholar 

  37. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10:1795–801.

    Article  PubMed  Google Scholar 

  38. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58:487–93.

    Article  CAS  PubMed  Google Scholar 

  39. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13:484–5.

    Article  PubMed  Google Scholar 

  40. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer. 2005;41:1542–6.

    Article  CAS  PubMed  Google Scholar 

  41. Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol. 2008;6:41–8.

    CAS  PubMed  Google Scholar 

  42. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27:23–44.

    Article  CAS  PubMed  Google Scholar 

  43. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13:797–801.

    Article  CAS  PubMed  Google Scholar 

  44. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 1993;11:2405–10.

    Article  CAS  PubMed  Google Scholar 

  45. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of Taxol. J Clin Oncol. 1991;9:1704–12.

    Article  CAS  PubMed  Google Scholar 

  46. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–47.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf. 2006;29:785–801.

    Article  CAS  PubMed  Google Scholar 

  48. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112:260–7.

    Article  CAS  PubMed  Google Scholar 

  49. Chen CL, Parameswaran R. Managing the risks of cardiac therapy in cancer patients. Semin Oncol. 2013;40(2):210–7.

    Article  PubMed  Google Scholar 

  50. Winter PC. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol. 2006;24:126–33.

    Article  CAS  PubMed  Google Scholar 

  51. Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol. 2005;2:356–63.

    Article  CAS  PubMed  Google Scholar 

  52. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3:27–34.

    Article  CAS  PubMed  Google Scholar 

  53. Yusuf SW, Razeghi P, Yeh ET. The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol. 2008;33:163–96.

    Article  PubMed  Google Scholar 

  54. Khorana AA. Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res. 2012;129:S10–5.

    Article  CAS  PubMed  Google Scholar 

  55. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin-based chemotherapy. J Urol. 1998;160:2021–4.

    Article  CAS  PubMed  Google Scholar 

  56. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–85.

    Article  CAS  PubMed  Google Scholar 

  57. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–9.

    Article  PubMed  Google Scholar 

  58. Calvo V, Ramirez N, Saura C, et al. Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: a meta-analysis. J Clin Oncol 2010;28:124s Suppl:abstr 1043.

    Google Scholar 

  59. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):175764.

    Article  Google Scholar 

  60. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in patients with cancer. J Clin Oncol. 2009;27:483947.

    Google Scholar 

  61. Leighl N, Bennouna J, Kuo H. Safety of bevacizumab treatment in non-small cell lung cancer (NSCLC) subjects receiving full-dose anticoagulation (FDAC) treated on protocol BO17704. Eur J Cancer. 2007;391 Suppl 5:abstr 6610.

    Google Scholar 

  62. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:9439.

    Article  Google Scholar 

  63. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.

    Article  CAS  PubMed  Google Scholar 

  64. Slovacek L, Ansorgova V, Macingova Z, Haman L, Petera J. Tamoxifen-induced QT interval prolongation. J Clin Pharm Ther. 2008;33(4):453–5.

    Article  CAS  PubMed  Google Scholar 

  65. Hedhli N, Kalinowski A, S Russel K. Cardiovascular effects of neuregulin-1/ErbB signaling: role in vascular signaling and angiogenesis. Curr Pharm Des 2014; 20(39): 4899–905

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133, Milano, Italy

    Angela Esposito, Carmen Criscitiello & Giuseppe Curigliano

  2. Maine Medical Center, Cardiovascular Institute, Portland, ME, USA

    Douglas B. Sawyer

Authors
  1. Angela Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen Criscitiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas B. Sawyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Curigliano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Curigliano .

Editor information

Editors and Affiliations

  1. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA

    Gretchen G. Kimmick

  2. Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Daniel J. Lenihan

  3. Maine Medical Center, Cardiovascular Institute, Portland, Maine, USA

    Douglas B. Sawyer

  4. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

    Erica L. Mayer

  5. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA

    Dawn L. Hershman

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

(PPTX 398 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Esposito, A., Criscitiello, C., Sawyer, D.B., Curigliano, G. (2017). Breast Cancer Cardio-Oncology. In: Kimmick, G., Lenihan, D., Sawyer, D., Mayer, E., Hershman, D. (eds) Cardio-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-43096-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43096-6_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43094-2

  • Online ISBN: 978-3-319-43096-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation